Journal of the American College of Surgeons
A patient care program focusing on early postoperative mobilisation, mandatory VTE risk stratification and electronic prophylaxis recommendations, significantly reduced likelihood of VTE complications from 1.9% to 0.3% (p < 0.01) and PE from 1.1% to 0.5% (p < 0.01).
Revised SPC: Nuvaring (ethinylestradiol/etonogestrel)
electronic Medicines Compendium
Further information on risk of venous thromboembolism has been added to a number of sections. Section 4.8 now lists arterial thromboembolism (rare) and chloasma (incidence unknown) as potential side-effects.
FDA approves Eloctate™ (antihaemophilic Factor (recombinant), Fc Fusion Protein) for haemophilia A
Biospace Inc.
The US FDA has approved Eloctate™ [Antihaemophilic Factor (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with haemophilia A.
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
